autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a leading biotechnology company focussed on the development and commercialisation of engineered t-cell therapies for haematological and solid tumours. autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient’s own cells.
Company profile
Ticker
AUTL
Exchange
Website
CEO
Christian Martin Itin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Exelixis • Acorda Therapeutics ...
Former names
Autolus Therapeutics Ltd
SEC CIK
AUTL stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
7 Aug 23
6-K
Index to Condensed Consolidated Financial Statements
3 Aug 23
6-K
Current report (foreign)
21 Jul 23
6-K/A
Current report (foreign) (amended)
6 Jul 23
6-K
Current report (foreign)
6 Jul 23
6-K
Current report (foreign)
20 Jun 23
6-K
Current report (foreign)
6 Jun 23
6-K
Current report (foreign)
6 Jun 23
6-K
Index to Condensed Consolidated Financial Statements
4 May 23
6-K
Current report (foreign)
14 Mar 23
Transcripts
AUTL
Earnings call transcript
2022 Q4
7 Mar 23
AUTL
Earnings call transcript
2022 Q3
5 Nov 22
AUTL
Earnings call transcript
2022 Q2
8 Aug 22
AUTL
Earnings call transcript
2022 Q1
8 May 22
AUTL
Earnings call transcript
2021 Q2
7 Aug 21
AUTL
Earnings call transcript
2021 Q1
10 May 21
AUTL
Earnings call transcript
2020 Q4
4 Mar 21
Latest ownership filings
SC 13G
Paradigm Biocapital Advisors LP
10 Jul 23
SC 13G
Tetragon Financial Management LP
20 Mar 23
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 23
SC 13G/A
Frazier Life Sciences Public Fund, L.P.
14 Feb 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
Syncona Portfolio Ltd
14 Feb 23
SC 13G/A
Deep Track Capital, LP
14 Feb 23
SC 13G/A
Capital World Investors
13 Feb 23
SC 13G
Deep Track Capital, LP
19 Dec 22
SC 13D/A
Blackstone Inc.
13 Dec 22
Financial summary
| Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q2 2023
88.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 72 |
| Opened positions | 13 |
| Closed positions | 8 |
| Increased positions | 19 |
| Reduced positions | 16 |
| 13F shares | Current |
|---|---|
| Total value | 256.29 bn |
| Total shares | 154.01 mm |
| Total puts | 7.00 k |
| Total calls | 110.60 k |
| Total put/call ratio | 0.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Syncona Portfolio | 21.35 mm | $50.81 bn |
| BX Blackstone | 20.49 mm | $48.76 bn |
| Qatar Investment Authority | 15.00 mm | $27.75 mm |
| Deep Track Capital | 15.00 mm | $35.70 bn |
| PPF Capital Partners Fund B.V. | 14.61 mm | $29.81 mm |
| Polygon Management | 12.00 mm | $28.56 bn |
| Tetragon Financial Management | 9.46 mm | $18.83 mm |
| Paradigm Biocapital Advisors | 9.22 mm | $21.94 bn |
| Armistice Capital | 7.26 mm | $17.29 bn |
| Nantahala Capital Management | 4.27 mm | $10.17 bn |
News
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia Published in the Journal Blood
5 Sep 23
Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia
17 Aug 23
Truist Securities Maintains Buy on Autolus Therapeutics, Raises Price Target to $9
17 Aug 23
Autolus Therapeutics Q2 EPS $(0.26) Misses $(0.22) Estimate
3 Aug 23
Earnings Scheduled For August 3, 2023
3 Aug 23